Latest News and Press Releases
Want to stay updated on the latest news?
-
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of Independent Scientific Research SOLANA BEACH,...
-
BRISTOL, Tenn., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) is drawing increased attention following its expansion into the $16.3 billion glaucoma market through a...
-
Idorsia nominates three Board Directors with outstanding pharmaceutical industry, management and financial expertise for election at the Annual General Meeting 2026 on May 6, 2026All Board members –...
-
Dublin, March 23, 2026 (GLOBE NEWSWIRE) -- The "Oncology Clinical Trials Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035" has been added to ResearchAndMarkets.com's...
-
CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy
-
TORONTO, March 20, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that St. Michael’s Hospital (SMH), part of Unity...
-
Phase 2 pivot évaluant lasmé-cel dans la LAL-B en rechute ou réfractaire (étude BALLI-01) en cours Phase 1 : 83 % d’ORR à la dose RP2D et 100 % d’ORR dans la population cible de phase 2.Population...
-
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 populationIn target Phase 2 population: 100% of patients became...
-
San Mateo, California, March 19, 2026 (GLOBE NEWSWIRE) -- SnapLogic, the Agentic Integration Company, today announced it has been positioned by Aragon Research, Inc. in the Leader section of the...
-
San Mateo, California, March 18, 2026 (GLOBE NEWSWIRE) -- SnapLogic, the Agentic Integration Company, today announced that it has been named as a Visionary by Gartner in the Magic Quadrant for...